Measurement of circulating parathyroid hormone (PTH) levels is essential for optimal management of mineral and bone disorders (MBD) in chronic kidney disease (CKD) patients. There are two major types of PTH assays currently in use: intact parathyroid hormone (i‐PTH) and whole PTH (w‐PTH) assays. The i‐PTH assay is the current standard, and considerable information regarding the management of CKD‐MBD has been obtained with this method. However, several limitations have been found with the i‐PTH assay. One limitation is that i‐PTH assay also measures fragments other than full‐length PTH (1‐84). Another limitation is the existence of multiple readout methods of the i‐PTH assay. The w‐PTH assay is theoretically ideal because it exclusively detects full‐length PTH (1‐84). However, clinical data proving the advantages of w‐PTH measurement are not sufficient. For uremic patients, Kidney Disease Improving Global Outcomes suggest that PTH levels should be maintained within approximately two to nine times the upper normal limit of the i‐PTH assays. The most critical issue in the evaluation of PTH levels is the lack of definitive PTH assay method. Evidence‐based recommendations on clinical management goals of PTH are warranted.
Therapeutic Apheresis and Dialysis – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud